Sun Pharm Company Profile

What is the competitive landscape for SUN PHARM

SUN PHARM has five hundred and fifty-four approved drugs.

There are forty-seven US patents protecting SUN PHARM drugs. There are eighteen tentative approvals on SUN PHARM drugs.

There are four hundred and ten patent family members on SUN PHARM drugs in fifty-eight countries and six hundred and twenty-eight supplementary protection certificates in nineteen countries.

Summary for Sun Pharm

International Patents:	410
US Patents:	47
Tradenames:	360
Ingredients:	332
NDAs:	554
Patent Litigation for Sun Pharm:	See patent lawsuits for Sun Pharm
PTAB Cases with Sun Pharm as petitioner:	See PTAB cases with Sun Pharm as petitioner

Drugs and US Patents for Sun Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	BACLOFEN	baclofen	TABLET;ORAL	077862-001	Aug 14, 2006		DISCN	No	No
Sun Pharm Industries	BACTRIM PEDIATRIC	sulfamethoxazole; trimethoprim	SUSPENSION;ORAL	017560-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Sun Pharm Industries	PREDNISONE	prednisone	TABLET;ORAL	089247-001	Dec 4, 1985	AB	RX	No	No
Sun Pharm Industries	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	TABLET;ORAL	075515-002	Oct 15, 2001		DISCN	No	No
Sun Pharm Industries	TEMAZEPAM	temazepam	CAPSULE;ORAL	071174-001	Jul 10, 1986		DISCN	No	No
Sun Pharm	WINLEVI	clascoterone	CREAM;TOPICAL	213433-001	Aug 26, 2020		RX	Yes	Yes	9,486,458

Expired US Patents for Sun Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sun Pharm Inds Inc	ABSORICA	isotretinoin	CAPSULE;ORAL	021951-001	May 25, 2012	8,952,064
Sun Pharm Inds Inc	ABSORICA	isotretinoin	CAPSULE;ORAL	021951-001	May 25, 2012	9,078,925
Sun Pharm Inds Inc	ABSORICA	isotretinoin	CAPSULE;ORAL	021951-003	May 25, 2012	8,952,064
Sun Pharm Inds Inc	ABSORICA	isotretinoin	CAPSULE;ORAL	021951-001	May 25, 2012	9,089,534
Sun Pharm Inds Inc	ABSORICA	isotretinoin	CAPSULE;ORAL	021951-003	May 25, 2012	9,078,925
Sun Pharm Industries	BACTRIM PEDIATRIC	sulfamethoxazole; trimethoprim	SUSPENSION;ORAL	017560-002	Approved Prior to Jan 1, 1982	RE28636

Paragraph IV (Patent) Challenges for SUN PHARM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Delayed-release Tablets	20 mg		2015-06-03
	Capsules	20 mg		2013-01-07
	Capsules	25 mg		2016-05-16
	Capsules	35 mg		2015-11-25
	Tablets	125 mg		2018-07-23
	Capsules	20 mg		2013-06-19
	Capsules	30 mg and 40 mg		2012-12-31

International Patents for Sun Pharm Drugs

Country	Patent Number	Estimated Expiration
Canada	2871039
European Patent Office	2969227
Hungary	E068643
Japan	2021008521
Russian Federation	2019136628
Russian Federation	2017106013

Supplementary Protection Certificates for Sun Pharm Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1343782	10C0037	France		PRODUCT NAME: PAZOPANIB; REGISTRATION NO/DATE: EU/1/110/628/001 20100614
1506211	132014902277722	Italy		PRODUCT NAME: UNA COMBINAZIONE DI DAPAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE E METFORMINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE COME PROTETTI DAL BREVETTO DI BASE EP1506211(XIGDUO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/900, 20140116
1506211	92496	Luxembourg		PRODUCT NAME: COMBINAISON DE DAPAGLIFLOZINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DE METFORMINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,TELLE QUE PROTEGEE PAR LE BREVET DE BASE EP1506211 B1
1020454	CR 2010 00015	Denmark		PRODUCT NAME: FEBUXOSTAT; REG. NO/DATE: EU/1/08/447/001-004 20080421
1412357	PA2008013,C1412357	Lithuania		PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
1746976	SPC/GB17/043	United Kingdom		PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT; REGISTERED: UK EU/1/16/1130 20161018

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Sun Pharm
• Sun Pharm Inds
• Sun Pharm Inds (in)
• Sun Pharm Inds Inc
• Sun Pharm Inds Ltd
• Sun Pharm Industries

Pharmaceutical Competitive Landscape Analysis: Sun Pharma – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Sun Pharmaceutical Industries Limited (Sun Pharma) has emerged as a formidable player, carving out a significant market position through strategic initiatives and robust growth. Let's dive into a comprehensive analysis of Sun Pharma's competitive landscape, exploring its market position, strengths, and strategic insights that have propelled it to the forefront of the global pharmaceutical arena.

Sun Pharma's Market Position

Sun Pharma has established itself as a leader in the pharmaceutical industry, both in India and globally. The company's market position is characterized by its extensive reach and dominant presence in key markets.

Global Presence

Sun Pharma operates in over 100 countries, showcasing its truly global footprint[6]. This expansive reach allows the company to diversify its revenue streams and minimize risks associated with any single market.

Market Leadership

Sun Pharma is ranked No. 1 and market share has increased from 7.8% to 8.2% in the over Rs. 2,214 Billion Indian pharmaceutical market as per AIOCD AWACS MAT Dec-2024[9].

This leadership position in the Indian market underscores Sun Pharma's strong domestic presence and brand recognition.

US Market Dominance

In the United States, Sun Pharma has established a significant presence:

• It is the 14th largest generics company in the USA[7].
• Ranked second by prescriptions in the US generic dermatology market[10].

This strong position in the US market, particularly in the generics segment, contributes substantially to Sun Pharma's global revenue and growth.

Key Strengths of Sun Pharma

Sun Pharma's success can be attributed to several key strengths that set it apart in the competitive pharmaceutical landscape.

Diverse Product Portfolio

Sun Pharma boasts an extensive product range spanning various therapeutic areas, including:

• Cardiology
• Psychiatry
• Gastroenterology
• Neurology
• Oncology
• Dermatology[6]

This diversification allows the company to cater to a wide range of medical needs and adapt to changing market demands.

Robust R&D Capabilities

Sun Pharma's commitment to research and development is evident in its significant investments and pipeline:

• Allocated approximately 9.2% of total revenue to R&D in fiscal year 2023[8].
• Strong pipeline of 13 NDAs and 95 ANDAs awaiting clearance from the USFDA[7].
• Specialty R&D pipeline includes five molecules currently undergoing clinical trials[7].

This focus on R&D enables Sun Pharma to continuously innovate and maintain its competitive edge in the market.

Strategic Acquisitions and Partnerships

Sun Pharma has leveraged strategic acquisitions to expand its market reach and capabilities:

• The acquisition of Ranbaxy Laboratories in 2014 significantly expanded Sun Pharma's global footprint[6].
• Ongoing strategic partnerships and acquisitions provide access to new markets, distribution networks, and expertise[6].

These strategic moves have played a crucial role in Sun Pharma's growth and market expansion.

Financial Performance and Growth Projections

Sun Pharma's financial performance and future projections paint a picture of steady growth and market expansion.

Recent Financial Results

For Q3 FY24-25, Sun Pharma reported impressive financial results:

• Revenue increased by 1294.76 Crore YoY[1].
• Net profit increased by 352.44 Crore YoY[1].
• Nine-month sales reached ₹12,710.0 crore, a 13.7% increase over the same period last year[1].

These figures demonstrate Sun Pharma's strong financial performance and consistent growth trajectory.

Future Growth Projections

Analysts forecast robust growth for Sun Pharma in the coming years:

• Revenue is projected to grow at a CAGR of 8.5% from 2023 to 2026[8].
• Projected revenue for fiscal year 2026 is estimated at INR 490 Billion[8].

These projections reflect the market's confidence in Sun Pharma's continued growth and expansion.

Strategic Initiatives and Focus Areas

Sun Pharma's strategic initiatives are focused on several key areas that are driving its growth and market position.

Specialty Drug Focus

Sun Pharma has placed a significant emphasis on developing and marketing specialty drugs:

• Specialty products contribute approximately 11% of the company's revenue (FY21)[5].
• Focus on high-margin areas like dermatology, oncology, and neurology[6].

This focus on specialty drugs differentiates Sun Pharma from competitors in the generics sector and contributes to higher profitability.

Emerging Market Expansion

Sun Pharma is actively expanding its presence in emerging markets:

• Emerging Markets (EM) Formulations sales reached US$277 million in Q3 FY24-25, a 10.1% increase year-over-year[1].
• EM sales contributed approximately 17% of total consolidated sales[1].

This expansion into emerging markets presents significant growth opportunities for Sun Pharma.

Digital Transformation

Sun Pharma is embracing digital transformation to enhance its operations and market reach:

• Investing in digital marketing and e-commerce platforms to reach customers directly.
• Implementing data analytics and artificial intelligence to optimize supply chain and manufacturing processes.

These digital initiatives are positioning Sun Pharma for future growth and efficiency gains.

Competitive Advantages

Sun Pharma's competitive advantages stem from its unique positioning and strategic focus areas.

Specialty Drug Portfolio

Sun Pharma's focus on specialty drugs provides several advantages:

• Higher profit margins compared to generic drugs.
• Less competition in niche therapeutic areas.
• Potential for long-term revenue streams from patented products.

Global Manufacturing Network

Sun Pharma's extensive manufacturing network includes:

• Over 40 manufacturing facilities across six continents.
• State-of-the-art production capabilities for various dosage forms.

This global manufacturing presence allows for efficient production and distribution, contributing to Sun Pharma's competitive edge.

Strong Brand Recognition

Sun Pharma has built strong brand recognition, particularly in India and emerging markets:

• Ranked No.1 by prescriptions in 12 doctor categories (SMSRC, July-Oct 2024)[1].
• Strong brand loyalty among healthcare professionals and patients.

This brand strength supports Sun Pharma's market position and growth potential.

Challenges and Risks

While Sun Pharma has numerous strengths, it also faces several challenges and risks in the competitive pharmaceutical landscape.

Regulatory Compliance

The pharmaceutical industry is heavily regulated, and Sun Pharma has faced regulatory challenges:

• Past issues with quality control and regulatory compliance have impacted market reputation[6].
• Ongoing need for significant investments in compliance and quality assurance.

Addressing these regulatory challenges remains a key focus area for Sun Pharma.

Price Erosion in Generic Markets

While Sun Pharma has diversified its portfolio, it still faces challenges in generic markets:

• High single-digit price erosion in generic drug markets[7].
• Increasing competition from other generic manufacturers.

Sun Pharma's focus on specialty drugs helps mitigate some of these pricing pressures.

Currency Fluctuations

As a global company, Sun Pharma is exposed to currency fluctuation risks:

• Fluctuations in exchange rates can impact revenue and profitability.
• Need for effective hedging strategies to manage currency risks.

Future Outlook and Strategic Direction

Looking ahead, Sun Pharma's future outlook appears promising, with several strategic directions guiding its growth.

Continued R&D Investment

Sun Pharma plans to increase R&D investments for both specialty and generic businesses[7]. This ongoing commitment to innovation will be crucial for maintaining its competitive edge.

Expansion of Specialty Drug Portfolio

The company is likely to continue expanding its specialty drug portfolio, focusing on high-value therapeutic areas and unmet medical needs.

Market Expansion

Sun Pharma will likely pursue further expansion in emerging markets, leveraging its strong brand and diverse product portfolio.

Digital Transformation

Continued investment in digital technologies and data analytics will be key to enhancing operational efficiency and market reach.

Key Takeaways

• Sun Pharma holds a leading position in the Indian pharmaceutical market and has a strong presence in the US generics market.
• The company's diverse product portfolio, robust R&D capabilities, and strategic acquisitions are key strengths.
• Focus on specialty drugs and expansion into emerging markets are driving growth and profitability.
• Sun Pharma faces challenges in regulatory compliance and price erosion in generic markets.
• Future growth is expected to be driven by continued R&D investment, expansion of the specialty drug portfolio, and digital transformation initiatives.

FAQs

1. What is Sun Pharma's market share in the Indian pharmaceutical market? Sun Pharma's market share has increased from 7.8% to 8.2% in the over Rs. 2,214 Billion Indian pharmaceutical market as of December 2024.

2. How much does Sun Pharma invest in Research and Development? Sun Pharma allocated approximately 9.2% of its total revenue to R&D in the fiscal year 2023.

3. What is Sun Pharma's position in the US generic dermatology market? Sun Pharma is ranked second by prescriptions in the US generic dermatology market.

4. What percentage of Sun Pharma's revenue comes from specialty products? As of FY21, specialty products contributed approximately 11% of Sun Pharma's revenue.

5. What is the projected CAGR for Sun Pharma's revenue from 2023 to 2026? Analysts forecast that Sun Pharma's revenue will grow at a CAGR of 8.5% from 2023 to 2026.

Sources cited: [1] https://www.bajajbroking.in/share-market-news/sun-pharmaceutical-industries-quarterly-results [5] https://groww.in/blog/analysis-sun-pharma-prospects [6] https://rankexdigital.com/swot-analysis-of-sun-pharma/ [7] https://blog.stockedge.com/analyzing-the-potential-of-sun-pharma-share/ [8] https://dcfmodeling.com/blogs/health/sunpharmans-financial-health [9] https://sunpharma.com/wp-content/uploads/2025/01/Press-Release-Sun-Pharma-Q3FY25-Financial-Result.pdf [10] https://sunpharma.com/about-us/